1. Home
  2. CRDL vs JHI Comparison

CRDL vs JHI Comparison

Compare CRDL & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • JHI
  • Stock Information
  • Founded
  • CRDL 2017
  • JHI 1971
  • Country
  • CRDL Canada
  • JHI United States
  • Employees
  • CRDL N/A
  • JHI N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • JHI Trusts Except Educational Religious and Charitable
  • Sector
  • CRDL Health Care
  • JHI Finance
  • Exchange
  • CRDL Nasdaq
  • JHI Nasdaq
  • Market Cap
  • CRDL 125.7M
  • JHI 124.3M
  • IPO Year
  • CRDL N/A
  • JHI N/A
  • Fundamental
  • Price
  • CRDL $1.28
  • JHI $13.74
  • Analyst Decision
  • CRDL Strong Buy
  • JHI
  • Analyst Count
  • CRDL 3
  • JHI 0
  • Target Price
  • CRDL $9.00
  • JHI N/A
  • AVG Volume (30 Days)
  • CRDL 391.0K
  • JHI 29.5K
  • Earning Date
  • CRDL 11-14-2024
  • JHI 01-01-0001
  • Dividend Yield
  • CRDL N/A
  • JHI 6.80%
  • EPS Growth
  • CRDL N/A
  • JHI N/A
  • EPS
  • CRDL N/A
  • JHI 1.05
  • Revenue
  • CRDL N/A
  • JHI N/A
  • Revenue This Year
  • CRDL N/A
  • JHI N/A
  • Revenue Next Year
  • CRDL N/A
  • JHI N/A
  • P/E Ratio
  • CRDL N/A
  • JHI $12.47
  • Revenue Growth
  • CRDL N/A
  • JHI N/A
  • 52 Week Low
  • CRDL $0.79
  • JHI $11.63
  • 52 Week High
  • CRDL $3.12
  • JHI $13.40
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 26.78
  • JHI 26.75
  • Support Level
  • CRDL $1.27
  • JHI $13.71
  • Resistance Level
  • CRDL $1.46
  • JHI $14.45
  • Average True Range (ATR)
  • CRDL 0.10
  • JHI 0.11
  • MACD
  • CRDL -0.00
  • JHI -0.07
  • Stochastic Oscillator
  • CRDL 3.33
  • JHI 6.31

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About JHI John Hancock Investors Trust

John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.

Share on Social Networks: